Zalicus Inc. (ZLCS) Completes Patient Enrollment in Two Phase 2 Clinical Studies of Z160 for Chronic Neuropathic Pain
9/3/2013 10:04:29 AM
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Zalicus Inc. (Nasdaq Capital Market: ZLCS), a biopharmaceutical company that discovers and develops novel treatments for patients suffering from pain, today announced that it has completed patient enrollment in two Phase 2 clinical studies of Z160 for chronic neuropathic pain indications including lumbosacral radiculopathy and postherpetic neuralgia. Top-line results of both studies are expected in the fourth quarter of 2013. Z160 is a first-in-class, oral, state-dependent, selective N-type calcium channel (Cav 2.2) blocker in development for chronic neuropathic pain.
Help employers find you! Check out all the jobs and post your resume.
comments powered by